Beijing Bohui Innovation and BOAOVAX End Collaboration on Rabies Vaccine Development

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (SHE: 300318), a biopharmaceutical company based in China, has announced an agreement with domestic firm BOAOVAX to terminate their collaboration on the development of a freeze-dried human rabies vaccine cultivated using serum-free Vero cells. As a result of this agreement, the clinical trials for the vaccine will be discontinued, and BOAOVAX will compensate Bohui Innovation with a payment of RMB 18 million. The partnership between the two companies was initially established in January 2020.- Flcube.com